<DOC>
	<DOCNO>NCT03085758</DOCNO>
	<brief_summary>This double-blind , placebo-controlled , randomize , multicenter proof concept dose-finding phase II study use two dos ADRECIZUMAB patient early septic shock bio-ADM plasma concentration admission &gt; 70 pg/ml .</brief_summary>
	<brief_title>Treatment Patients With Early Septic Shock Bio-Adrenomedullin ( ADM ) Concentration &gt; 70 pg/ml With ADRECIZUMAB</brief_title>
	<detailed_description>This double-blind , placebo-controlled , randomize , multicenter proof concept dose-finding phase II study use two dos ADRECIZUMAB patient early septic shock bio-ADM plasma concentration admission &gt; 70 pg/ml . `` Early '' septic shock define life-threatening organ dysfunction due dysregulated host response proven suspect infection lead decline Mean Arterial Pressure ( MAP ) &lt; 65 mmHg , refractory fluid resuscitation require vasopressor . Early define maximum less 12 hour onset cardiovascular organ-dysfunction administration ADRECIZUMAB . Refractoriness fluid resuscitation define lack response administration 30 mL fluid per kilogram body weight determine accord clinician 's assessment inadequate hemodynamic result . It intend enroll 300 patient surgical , medical mixed ICU multiple center Europe . All patient treat accord `` International Guidelines Management Severe Sepsis Septic Shock '' . Eligible patient ( confirmed central verification ) randomize ( 1:1:2 ) ADRECIZUMAB treatment arm A ( 2 mg/kg ) ADRECIZUMAB treatment arm B ( 4 mg/kg ) placebo control group . Patients assign treatment arm A B administer single dose ADRECIZUMAB intravenous infusion approximately 1 hour ; patient assign control group administer placebo intravenous infusion approximately 1 hour . As long patient ICU , daily measurement clinical sign laboratory data collect safety reason determination Sequential Organ Failure Assessment Score ( SOFA score ) . Additional blood sample central laboratory analysis take inclusion day 1 , day 3 , day 5 , day 7 day discharge ( whatever come first ) measurement biomarkers . The SOFA score component determine daily patient entire stay ICU ( 28 day discharge whatever come first ) . Safety monitor patient begin time sign Informed Consent Form continue 90 day end short-term infusion study medication . At select study center pharmacokinetic ( PK ) substudy perform determine profile ADRECIZUMAB 80 randomize patient . An interim analysis efficacy plan 50 % patient complete study ( n=150 ) .</detailed_description>
	<mesh_term>Shock</mesh_term>
	<mesh_term>Shock , Septic</mesh_term>
	<mesh_term>Adrenomedullin</mesh_term>
	<criteria>1 . Written informed consent patient legal representative ( accord country specific regulation ) 2 . Male female patient , age ≥ 18 year 3 . Body weight 50 kg 120 kg 4 . BioADM concentration &gt; 70 pg/ml 5 . Patient early septic shock ( start vasopressor therapy &lt; 12 hour ) 1 . Moribund death consider imminent &lt; 28 day 2 . Preexisting unstable condition ( e.g . recent cerebral hemorrhage infarct , recent acute unstable myocardial infarction ( &lt; 3 month ) , congestive heart failure New York Heart Association ( NYHA ) Class IV 3 . Patients require cardiopulmonary resuscitation last 4 week prior evaluation enrollment 4 . Severe Chronic Obstructive Pulmonary Disease ( COPD ) chronic oxygen need home ( GOLD IV ) 5 . Any organ bone marrow transplant within past 24 week 6 . Uncontrolled serious hemorrhage ( ≥ 2 unit blood / platelet previous 24 hrs. ) . Patients may consider enrollment bleed stop patient otherwise qualified 7 . Uncontrolled hematological / oncological malignancy 8 . Immunosuppressed patient ( know HIV , absolute neutropenia &lt; 500 per µL ) 9 . Treatment immunosuppressive drug 10 . Severe chronic liver disease ( ChildPugh C ) 11 . Systemic fungal infection active tuberculosis 12 . Neuromuscular disorder impact breathe / spontaneous ventilation 13 . Burns &gt; 30 % body surface 14 . Plasmapheresis 15 . Women pregnant nursing 16 . Participation clinical trial involve another investigational drug within 4 week prior inclusion 17 . Unwilling unable fully evaluate followup visit</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2017</verification_date>
	<keyword>Early Septic Shock</keyword>
</DOC>